Literature DB >> 30723758

Development data associated with effects of stiffness softening of 3D-TIPS elastomer nanohybrid scaffolds on tissue ingrowth, vascularization and inflammation in vivo.

Linxiao Wu1, Adrián Magaz1, Elizabeth Maughan2, Nina Oliver1, Arnold Darbyshire1, Marilena Loizidou1, Mark Emberton1, Martin Birchall2, Wenhui Song1.   

Abstract

This DiB article contains data related to the research article entitled "Cellular responses to thermoresponsive stiffness memory elastomer nanohybrid scaffolds by 3D-TIPS" (Wu et al., 2018). Thermoresponsive poly (urea-urethane) nanohybrid elastomer (PUU-POSS) scaffolds were implanted in rats for up to 3 months. The porous structure and tensile mechanical properties of the scaffolds are listed and compared before and after in vitro and in vivo tests. The details of the histological analysis of the explants with different initial stiffness and porous structures at various time points are presented. The images and data presented support the conclusion about the coupled effects of stiffness softening and the hierarchical porous structure modulating tissue ingrowth, vascularization and macrophage polarization in the article (Wu et al., 2018).

Entities:  

Year:  2019        PMID: 30723758      PMCID: PMC6352546          DOI: 10.1016/j.dib.2019.01.012

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications table Value of the data Data presented in this article provide direct comparison of the stiffness softening and hierarchical structure of the 3D-TIPS scaffolds before and after in vitro and in vivo tests. The data magnify more insights about the changes of structures at multi-scales and mechanical properties of the scaffolds under biophysical and biological conditions. The histological images of the scaffolds with different initial stiffness and porous structure by immunohistochemistry elucidate for the first time how the stiffness softening and digitally printed hierarchical porous structure regulate tissue ingrowth, vascularization and macrophage polarization towards an M2 phenotype at the early (week 4) and late (week 12) stages in vivo.

Data

Table 1 shows the stiffness softening effect of the scaffolds in vitro over day 0–28 and how they relax towards their intrinsic elasticity. The dimensions of the 3D printed preforms and the scaffolds as produced are shown in Table 2. Table 3, Table 4, Table 5, Table 6, Table 7 show the effects of softening during in vivo implantation at various time points, in terms of tensile mechanical properties and XRD characterization respectively. Fig. 1, Fig. 2, Fig. 3 depict low and high magnification of Hematoxylin and Eosin (H&E) and Masson׳s trichrome (M&T) staining showing collagen fibre orientation and tissue ingrowth within the explants. Table 8 quantifies the angiogenic response of the explants during implantation time with stiffness softening. The softening effects on macrophage polarization (M1 markers CD86, CD63 and M2 maker CD163) and T-cell response (markers CD3 and CD4) are quantified in Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15; representative immunohistochemistry images are shown in Fig. 4, Fig. 5, Fig. 6, Fig. 7, Fig. 8, Fig. 9, Fig. 10, Fig. 11, Fig. 12, Fig. 13.
Table 1

Stiffness softening of PUU-POSS scaffolds with 50% infill density, tested at wet condition before and after in vitro incubation at 37 over 28 days.

3D-TIPS scaffold, 50% infillTensile Modulus (at 50% strain) MPaTensile Modulus (at 100% strain) MPaUltimate tensile strength (breaking point), MPaStrain at break, %Toughness, Jm−3×104
50CCDay 00.98 (±0.14)0.82 (±0.21)1.33 (±0.09)179 (±8)137 (±22)
Day 280.45 (±0.08)0.40 (±0.11)0.77 (±0.15)230 (±13)115 (±20)
50CC+HDay 00.53 (±0.02)0.44 (±0.08)0.76 (±0.05)236 (±19)113 (±27)
Day 280.39 (±0.09)0.32 (±0.08)0.72 (±0.12)240 (±18)110 (±14)
50RTC+HDay 00.44 (±0.06)0.39 (±0.09)0.67 (±0.03)146 (±15)146 (±12)
Day 280.42 (±0.08)0.38 (±0.10)0.65 (±0.06)149 (±19)146 (±20)
Table 2

Dimensions of 3D-printed PVA preforms and PUU-POSS scaffolds made by 3D-TIPS.

Scaffoldx- Strut thickness (μm, n=10)y-Strut thickness (μm, n=10)z-Strut thickness (μm, n=10)Sample Size, (L×W×T, mm) (n=6)Apparent Volume (mm3)Volume Swelling Ratio vs VPVA(%)
50% infill PVA preform (mould)40040020060.0 × 12.0 × 4.02880 ± 4
50CCWet, as produced, RT197 ± 13157 ± 9118 ± 1961.0 × 13.0 × 3.62855 ± 9−0.9 ± 0.2
50CC+HWet, as produced, RT176 ± 8150 ± 8121 ± 1459.7 × 11.3 × 3.52361 ± 7−18.0 ± 0.1
50RTC+HWet, as produced, RT186 ± 10140 ± 11127 ± 1058.9 × 12.7 × 3.92917 ± 131.2 ± 0.3
Table 3

Tensile modulus (at 50% strain) of the scaffold explants at weeks 4, 8 and 12.

Tensile modulus (MPa)50CC50CC+H50RTC+H
Week 01.11 (±0.13)0.77 (±0.09)0.43 (±0.08)
Week 42.45 (±0.40)2.13 (±1.38)1.56 (±0.20)
Week 83.99 (±0.55)3.73 (±0.78)3.13 (±0.88)
Week 126.97 (±1.46)6.08 (±1.35)5.88 (±1.53)
Table 4

Strain at break of the scaffold explants at weeks 4, 8 and 12.

Strain at break (%)50CC50CC+H50RTC+H
Week 0179 (±18)186 (±19)146 (±15)
Week 4340 (±24)310 (±61)291 (±70)
Week 8444 (±73)423 (±71)406 (±122)
Week 12521 (±70)494 (±65)454 (±80)
Table 5

Ultimate tensile strength (breaking point) of the scaffold explants at weeks 4, 8 and 12.

Ultimate tensile strength (MPa)50CC50CC+H50RTC+H
Week 01.63 (±0.09)0.99 (±0.05)0.67 (±0.07)
Week 41.07 (±0.39)1.01 (±0.45)0.81 (±0.18)
Week 81.98 (±0.37)1.86 (±0.53)1.16 (±0.39)
Week 122.84 (±0.53)2.60 (±0.75)2.44 (±0.29)
Table 6

Toughness of the scaffold explants at weeks 4, 8 and 12.

Toughness (J m−3 104)50CC50CC+H50RTC+H
Week 0137 (±12)146 (±12)113 (±17)
Week 4412 (±24)370 (±66)351 (±79)
Week 8523 (±73)463 (±81)406 (±162)
Week 12599 (±99)524 (±77)444 (±90)
Table 7

Analysis of WAXD spectra of the explants during implantation. Degree of crystallinity (Dc, %), d-spacing (d, A) of semicrystalline structure and broad halo peaks of amorphous structures.

ScaffoldsWeek 0
Week 4
Week e8
Week 12
2θdDcdDcdDcdDc
50CCSharp peak 120.04.437.6
Sharp peak 223.23.8
Broad halo peak 1
Broad halo peak 220.1
Broad halo peak 330.030.531.2
Broad halo peak 440.541.541.9
50CC+HSharp peak 1
Sharp peak 2
Broad halo peak 1
Broad halo peak 219.219.220.0
Broad halo peak 330.328.829.830.9
Broad halo peak 441.342.142.242.2
50RTC+HSharp peak 1
Sharp peak 2
Broad halo peak 1
Broad halo peak 219.3
Broad halo peak 326.025.927.027.1
Broad halo peak 442.342.042.741.6
Fig. 1

Hematoxylin & Eosin (H&E) stained histological structure of middle in-plane of 50CC scaffold explants at week 12 depicting tissue ingrowth within the scaffold network, ×2 magnifications.

Fig. 2

Subcutaneous implantation of 50CC+H scaffolds at week 12: (A) tissue integration of middle-in-plane of the 50CC+H scaffold by Hematoxylin and Eosin (H&E) staining, (B) collagen production by Masson׳s trichrome staining (M&T), (C) endothelial cell infiltration as identified by CD31 staining, used as a marker of angiogenesis; (D-F) enlarged views of middle-in-plane sections respectively. (G-I) Middle cross-sectional view and (J-L) enlarged middle cross-sectional view.

Fig. 3

Subcutaneous implantation of 50RTC+H scaffolds at week 12: (A) tissue integration of middle-in-plane of the 50RTC+H scaffold by Hematoxylin and Eosin (H&E) staining, (B) collagen production by Masson׳s trichrome staining, (C) endothelial cell infiltration as identified by CD31 staining, used as a marker of angiogenesis; (D-F) enlarged middle-in-plane views respectively. (G-I) Middle cross-sectional view and (J-L) enlarged middle cross-sectional view.

Table 8

Proportion of total tissue/scaffold volume occupied by blood capillaries at weeks 4, 8 and 12. Immunofluorescent staining of anti-CD31 marker for blood capillaries.

Capillary (%)50CC50CC+H50RTC+H
Week 411 (±1)6 (±2)3 (±2)
Week 825 (±3)12 (±4)8 (±4)
Week 1230 (±4)20 (±5)14 (±5)
Table 9

Host pan-macrophage/monocyte response (CD68+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point).

CD68+50CC50CC+H50RTC+H
Week 4353 (±54)301 (±56)210 (±46)
Week 8322 (±48)260 (±39)164 (±48)
Week 12228 (±39)201 (±43)115 (±52)
Table 10

Host macrophage response (CD86+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point).

CD86+50CC50CC+H50RTC+H
Week 4397 (±56)289 (±47)152 (±39)
Week 8312 (±55)224 (±51)132 (±45)
Week 12271 (±41)186 (±55)96 (±53)
Table 11

Host macrophage response (CD163+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point).

CD163+50CC50CC+H50RTC+H
Week 4360 (±64)294 (±65)78 (±36)
Week 8531 (±88)434 (±76)103 (±67)
Week 12679 (±94)534 (±78)167 (±46)
Table 12

Ratio of CD68+/ CD163+ of the various scaffold groups at weeks 4, 8 and 12.

CD68+/CD163+50CC50CC+H50RTC+H
Week 40.981.022.69
Week 80.600.591.59
Week 120.330.380.68
Table 13

Ratio of CD86+/ CD163+ of the various scaffold groups at weeks 4, 8 and 12.

CD86+/CD163+50CC50CC+H50RTC+H
Week 41.100.981.95
Week 80.590.521.28
Week 120.400.350.57
Table 14

Host T lymphocyte response (CD3+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffolds per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point).

CD3+50CC50CC+H50RTC+H
Week 4372 (±54)301 (±56)134 (±31)
Week 8232 (±48)204 (±39)67 (±15)
Week 12156 (±44)109 (±43)35 (±8)
Table 15

Host T lymphocyte response (CD4+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffolds per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point).

CD4+50CC50CC+H50RTC+H
Week 4301 (±61)245 (±71)152 (±27)
Week 8252 (±42)201 (±46)102 (±28)
Week 12122 (±32)87 (±45)32 (±16)
Fig. 4

Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD68 (M1 pan-macrophage/monocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.

Fig. 5

Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD68 (pan-macrophage/monocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-I) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm.

Fig. 6

Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD86 (M1 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.

Fig. 7

Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD86 (M1 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm.

Fig. 8

Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD163 (M2 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.

Fig. 9

Immunohistochemistry of the host macrophage response towards scaffolds in vivo at weeks 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD163 (M2 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm.

Fig. 10

Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD3 (T lymphocyte marker) staining at (A-C, G-L) ×4 and (D-F, J-L) ×40 magnifications.

Fig. 11

Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD3 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat spleen). Scale bar: 100 μm.

Fig. 12

Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD4 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.

Fig. 13

Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD4 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat spleen). Scale bar: 100 μm.

Static tensile mechanical properties and hierarchical porous structure of the scaffolds

Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7. Stiffness softening of PUU-POSS scaffolds with 50% infill density, tested at wet condition before and after in vitro incubation at 37 over 28 days. Dimensions of 3D-printed PVA preforms and PUU-POSS scaffolds made by 3D-TIPS. Tensile modulus (at 50% strain) of the scaffold explants at weeks 4, 8 and 12. Strain at break of the scaffold explants at weeks 4, 8 and 12. Ultimate tensile strength (breaking point) of the scaffold explants at weeks 4, 8 and 12. Toughness of the scaffold explants at weeks 4, 8 and 12. Analysis of WAXD spectra of the explants during implantation. Degree of crystallinity (Dc, %), d-spacing (d, A) of semicrystalline structure and broad halo peaks of amorphous structures.

Cellular infiltration and matrix deposition

Fig. 1, Fig. 2, Fig. 3. Hematoxylin & Eosin (H&E) stained histological structure of middle in-plane of 50CC scaffold explants at week 12 depicting tissue ingrowth within the scaffold network, ×2 magnifications. Subcutaneous implantation of 50CC+H scaffolds at week 12: (A) tissue integration of middle-in-plane of the 50CC+H scaffold by Hematoxylin and Eosin (H&E) staining, (B) collagen production by Masson׳s trichrome staining (M&T), (C) endothelial cell infiltration as identified by CD31 staining, used as a marker of angiogenesis; (D-F) enlarged views of middle-in-plane sections respectively. (G-I) Middle cross-sectional view and (J-L) enlarged middle cross-sectional view. Subcutaneous implantation of 50RTC+H scaffolds at week 12: (A) tissue integration of middle-in-plane of the 50RTC+H scaffold by Hematoxylin and Eosin (H&E) staining, (B) collagen production by Masson׳s trichrome staining, (C) endothelial cell infiltration as identified by CD31 staining, used as a marker of angiogenesis; (D-F) enlarged middle-in-plane views respectively. (G-I) Middle cross-sectional view and (J-L) enlarged middle cross-sectional view.

Angiogenesis response

Table 8. Proportion of total tissue/scaffold volume occupied by blood capillaries at weeks 4, 8 and 12. Immunofluorescent staining of anti-CD31 marker for blood capillaries.

T-cell proliferative and host macrophage response

Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15 and Fig. 4, Fig. 5, Fig. 6, Fig. 7, Fig. 8, Fig. 9, Fig. 10, Fig. 11, Fig. 12, Fig. 13. Host pan-macrophage/monocyte response (CD68+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point). Host macrophage response (CD86+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point). Host macrophage response (CD163+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point). Ratio of CD68+/ CD163+ of the various scaffold groups at weeks 4, 8 and 12. Ratio of CD86+/ CD163+ of the various scaffold groups at weeks 4, 8 and 12. Host T lymphocyte response (CD3+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffolds per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point). Host T lymphocyte response (CD4+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffolds per unit square (Nv/mm2) at week 4, 8 and 12 (n = 20 frames, 12 scaffolds in each group at each time point). Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD68 (M1 pan-macrophage/monocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD68 (pan-macrophage/monocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-I) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm. Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD86 (M1 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD86 (M1 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm. Immunohistochemistry of the host macrophage response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD163 (M2 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. Immunohistochemistry of the host macrophage response towards scaffolds in vivo at weeks 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD163 (M2 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm. Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD3 (T lymphocyte marker) staining at (A-C, G-L) ×4 and (D-F, J-L) ×40 magnifications. Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD3 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat spleen). Scale bar: 100 μm. Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD4 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. Immunohistochemistry of the host T lymphocyte response towards scaffolds in vivo at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD4 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat spleen). Scale bar: 100 μm.

Experimental design, materials and methods

Fabrication of thermoresponsive PUU-POSS scaffolds

A 3D-TIPS technique, based on reverse 3D printing and phase separation of the polymer solution, as described in [1], was used to manufacture PUU-POSS scaffolds (50% infill density) at different thermal conditions (50CC, 50CC+H and 50RTC+H).

Characterization of the scaffolds prior to implantation

An Instron 5655 was applied to test static tensile mechanical properties of the scaffolds, before and after incubation over 28 days at body temperature, as described in [1], as well the explants after implantation in rats for 4, 8 and 12 weeks. The dimensions of the printed preforms and the scaffold as produced were also measured and estimated.

Characterization of the scaffold explants

As detailed in [1], the scaffolds were subcutaneously implanted in adult male rats and harvested at different time points. The physico-mechanical properties (i.e. tensile properties and phase structure) were then analyzed with an Instron 5655 tester and an X-ray diffractometer. Sectioning and histological staining (i.e. H&E and M&T) were carried out, and collagen fiber formation and tissue ingrowth orientation was quantified as previously described [1]. Immunofluorescent staining against capillary marker CD31, macrophage markers CD86/CD68/CD163 and T-cell makers CD3/CD4 was carried out, and the number of positive stained cells was quantified as described in [1].
Subject areaChemistry, biology
More specific subject areaBiomaterials
Type of dataTables, Figures
How data were acquiredStatic tensile mechanical testing (Instron5655), Mercury intrusion porosimeter (Quantachrome Poremaster 60GT), X-ray diffraction (XRD; Bruker D8 Advance), immunohistochemistry
Data formatAnalyzed
Experimental factorsScaffolds prior to implantation were subjected to uniaxial mechanical testing and mercury intrusion porosimeter. Scaffold explants at different time points were subjected to uniaxial mechanical testing and XRD characterized. In addition, explants were sectioned and stained for Hematoxylin and Eosin (H&E) and Masson׳s trichrome (M&T). Immunofluorescent staining was carried out to detect presence of capillary markers (i.e. CD31), macrophage markers (i.e. CD86, CD68, CD163) and T-cell makers (i.e. CD3, CD4).
Experimental featuresPhysico-mechanical characterization, histology and immunohistochemistry
Data source locationCentre for Biomaterials in Surgical Reconstruction and Regeneration, Division of Surgery & Interventional Science, University College London, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom, NW3 2PF
Data accessibilityWithin this article
Related research article[1]L. Wu, A. Magaz, E. Maughan, N. Oliver, A. Darbyshire, M. Loizidou, M. Emberton, M. Birchall, W. Song, Cellular responses to thermoresponsive stiffness memory elastomer nanohybrid scaffolds by 3D-TIPS, Acta Biomater. (2018).doi:10.1016/j.actbio.2018.12.019.
  1 in total

1.  Cellular responses to thermoresponsive stiffness memory elastomer nanohybrid scaffolds by 3D-TIPS.

Authors:  Linxiao Wu; Adrián Magaz; Elizabeth Maughan; Nina Oliver; Arnold Darbyshire; Marilena Loizidou; Mark Emberton; Martin Birchall; Wenhui Song
Journal:  Acta Biomater       Date:  2018-12-14       Impact factor: 8.947

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.